Rezolute, Inc. · NASDAQ:RZLT
Rezolute — AntriaBio — Investor Presentation (February 2014)
17 slides from Rezolute's investor presentation, Feb 5, 2014
Slide 1: AntriaBio February 2014
antriabio February 2014 (OTCQB: ANTB)
Slide 2: Safe Harbor
Safe Harbor Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-loo
Slide 3: Overview
Overview We are a biopharmaceutical company developing therapies to treat diabetes by combining our proprietary formulation and manufacturing capabilities with FDA-approved therapeutics Lead Product Candidate: AB101 “a once-a-week basal insulin injection”
Slide 4: Corporate Highlights
Corporate Highlights = Disruptive Formulation with Potential to Transform Huge Market = Rapidly Growing > $8 Billion in Annual Sales = Promising Pre-clinical Results Support Advancement into Clinical Studies in Humans in 2014 = Product Development Strategy with Clear Path to Registration and Expecte
Slide 5: Diabetes
Diabetes A metabolic disease characterized by high blood sugar primarily as a result of inability of pancreas to produce enough insulin = Chronic disease which can lead to complications including heart disease kidney failure, blindness and amputation — Type | & Type II forms of the disease * Treatme
Slide 6: Insulin Replacement Therapy
Insulin Replacement Therapy OVERVIEW {Insulin produced by pancreas — * Basal insulin: background insulin always produced by the pancreas, whether or not we eat * Bolus insulin: extra insulin the pancreas makes in response to the we eat; amount of bolus insulin produced depends on type and size of me
Slide 7: The Diabetes Market
The Diabetes Market "Number and Percentage of U.S. Population with Diagnosed Diabetes, 4958-2010 "Today 300M+ suffering from diabetes worldwide including > 25M in the US * In 2012 market for insulin replacement therapy (basal and bolus) was more than $128 = Basal insulin accounts for more than $8B o
Slide 8: The Therapeutic Challenge
The Therapeutic Challenge REFILL YOUR PRESCRIPTION = > Frequent Discomfort Irritating! Awkward! Confusing! il Compliance is a Daunting Task! antriabio
Slide 9: The Opportunity (AB101)
The Opportunity (AB101) AB101 is a once-a-week injectable basal insulin formulation PRODUCT OVERVIEW = Targeted for both Type 1 and Type 2 diabetes = Releases insulin uniformly over one week = Low, sustained insulin level that supplements effects of bolus insulin What is the real value proposition?
Slide 10: +$8 Billion: Hypothetical Landscape
+$8 Billion: Hypothetical Landscape Potential to Leapfrog the standard of care! a tresiba _ Sone s ° ; 5 : aseajay papuoixy
Slide 11: The Science Underlying AB101
The Science Underlying AB101 The Goal: To formulate human basal insulin into injectable microspheres that will steady dissolve, releasing low but sustained levels of insulin into the blood stream. Patented Formulation Method: Increase the solubility of the insulin molecule through a process called P
Slide 12: AB101 Promising Preclinical Results
AB 101 Promising Preclinical Results = Minimal burst of drug: Minimal release of insulin (less than 1% of weekly dose) immediately after injection followed by sustained insulin release = Repeatable kinetics: Pattern and magnitude of drug release is nearly identical across multiple injections = Stead
Slide 13: AB101 Clinical Plan
AB 101 Clinical Plan Objective: Demonstrate safety, tolerability and indication of efficacy of AB 101 in 2014 and then pursue approval in US and Europe * Toxicity and overall pharmacology to be studied in rabbits, dogs, guinea pigs and rodents in 2014 ™ Phase 1/2A 20 patient study planned for second
Slide 14: Robust Intellectual Property Estate
Robust Intellectual Property Estate = Formulation: PEGylated bioactive agents in biodegradable polymers including PEG-insulin in PLGA; Patent No. 6,706,289, Issued 2004, Expiration 2021. ™ Delivery Technology: Site-specific PEGylation method for proteins including insulin; Publication 2004; Expirati
Slide 15: Near-Term Value Creating Milestones
Near-Term Value Creating Milestones 2014 Commence AB 101 Toxicity and Pharmacology Studies in rabbits, dogs, guinea pigs and rodents Hire and retain additional critical scientific and engineering staff Commence work on additional pipeline ‘opportunities Produce AB101 material in a cGMP suite Complet
Slide 16: Selected Members of Management and Board
Selected Members of Management and Board Nevan Elam Chairmanand CEO + CEO AeroSurgical + SVP Nektar Therapeutics — Sold division to Novartis for $200M enterprise value ~ Spun out Pearl Therapeutics, acquired for S1Bby Astra Zeneca + CFOE2Open, NASDAQ, ‘market cap. > 600M + Former Wilson, Sonsini Par
Slide 17: AntriaBio
antriabio Ticker: ANTB AntriaBio, Inc.